Psoriatic Arthritis
Conditions
Brief summary
The proportion of subjects who achieve ACR20 at Week 24
Detailed description
The proportion of subjects achieving ACR50 at Week 24, The change from baseline in HAQ-DI at Week 24., The proportion of subjects achieving PASI75 response at Week24 among subjects with BSA ≥3% at baseline, The proportion of subjects achieving ACR70 at Week 24, The change from baseline in the van der Heijde modified total Sharp score at Week 24, The change from baseline in the van der Heijde modified total Sharp score at Week 16
Interventions
Sponsors
Sun Pharmaceutical Industries Limited, Iqvia Biotech Limited, Labcorp Central Laboratory Services SARL
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of subjects who achieve ACR20 at Week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of subjects achieving ACR50 at Week 24, The change from baseline in HAQ-DI at Week 24., The proportion of subjects achieving PASI75 response at Week24 among subjects with BSA ≥3% at baseline, The proportion of subjects achieving ACR70 at Week 24, The change from baseline in the van der Heijde modified total Sharp score at Week 24, The change from baseline in the van der Heijde modified total Sharp score at Week 16 | — |
Countries
Czechia, Germany, Poland, Spain
Outcome results
None listed